

Summary of prescribing and medicines optimisation scheme (PMOS) 2026 to 2027

Area	Aim
Antimicrobial resistance project 1	Reduce the number of patients prescribed more than 5 day courses of doxycycline
Antimicrobial resistance project 2	Antibiotic prescribing improvement scheme – children prescribed antibiotics in primary care
Chronic Kidney disease (CKD)	<p>Improve diagnosis and coding of patients with CKD</p> <p>Offer holistic reviews to patients with new diagnosis and other high-risk patients</p>
High risk patient reviews – Gabapentinoids and opioids	Provide medication reviews to patients co-prescribed gabapentinoids and opioids
Specific oral nutritional supplements (ONS) product reviews	Specific ONS products update anthropometry (patient measurements) and malnutrition screening (MUST) and switch to a more cost-effective ONS
Respiratory project	Reduce the number of patients with asthma who are prescribed more than 6 SABA inhalers per year. (Continued from 2025 to 2026)
Rheumatology	<p>Ensure that all denosumab is prescribed as the biosimilar Zadenvi</p> <ul style="list-style-type: none"> • Switch current patients • All new prescriptions
Valproate	<p>Ensure that all female patients under 55yrs prescribed valproate are under specialist review and have an up-to-date Annual Risk Acknowledgement Form or have been referred.</p> <p>Ensure the practice has actioned the September 2024 MHRA alert regarding valproate prescribing in men.</p>